To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g. HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to be assessed. From 114 HIV-1 subtype C clinical samples (36 ARV-na？ve, 78 ARV-exposed), pol amplicons were produced and analyzed for phenotypic resistance using both a subtype B- and C-backbone in which the pol fragment was deleted. Phenotypic resistance was assessed in resulting recombinant virus stocks (RVS) for a series of antiretroviral drugs (ARV's) and expressed as fold change (FC), yielding 1660 FC comparisons. These Antivirogram？ derived FC values were categorized as having resistant or sensitive susceptibility based on biological cut-off values (BCOs). The concordance between resistance calls obtained for the same clinical sample but derived from two different backbones (i.e. B and C) accounted for 86.1% (1429/1660) of the FC comparisons. However, when taking the assay variability into account, 95.8% (1590/1660) of the phenotypic data could be considered as being concordant with respect to their resistance call. No difference in the capacity to detect resistance associated with M184V, K103N and V106M mutations was noted between the two backbones. The following was concluded: (i) A high level of concordance was shown between the two backbone phenotypic resistance profiles; (ii) Assay variability is largely responsible for discordant results (i.e. for FC values close to BCO); (iii) Confidence intervals should be given around the BCO's, when assessing resistance in HIV-1 subtype C; (iv) No systematic resistance under- or overcalling of subtype C amplicons in the B-backbone was observed; (v) Virus backbone subtype sequence variability outside the pol region does not contribute to phenotypic FC values. In conclusion the HXB2 virus backbone remains an acceptable vector for phenotyping HIV-1 subtype C pol amplicons.
References
[1]
WHOUNICEFUNAIDS (2010) Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Geneva, World Health Organization. Available:http://www.who.int/hiv/pub/2010progressr？eport/full_report_en.pdf. Accessed 28 May 2011.
[2]
Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TR, et al. (2008) The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antiviral Therapy 13: 625–639.
[3]
Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, et al. (2011) HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS Jul 31;25: 1461–1469.
[4]
Price M, Wallis C, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses Jan 27: 5–12.
[5]
Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis Jul 27.
[6]
Hamers RL, Siwale M, Wallis CL, Labib M, van Hasselt R, et al. (2010) HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. Journal of acquired immune deficiency syndromes (1999) 55: 95–101. Available:http://www.ncbi.nlm.nih.gov/pubmed/20585？262.
[7]
Ndembi N, Hamers R, Sigaloff K, Lyagoba F, Magambo B, et al. (2011) Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS Apr 24; 25: 905–910.
[8]
Hemelaar J, Gouws E, Ghys PD, Osmanov S (2011) Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS Mar 13; 25: 679–689. doi:10.1097/QAD.0b013e328342ff93.
[9]
VanZyl G, VanderMerwe L, Claassen M, Zeier M, Preiser W (2011) Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. J Med Virol Oct; 83: 1764–1769.
[10]
Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after virologic failure of first-line ART in South Africa. AIDS 24: 1007–1012.
[11]
Virco BVBA (n.d.) Belgium. Available:http://www.vircolab.com/hiv-resistance-p？roducts/antivirogram. Accessed 2 March 2011.
[12]
Hertogs K, de Béthune M, Miller V, Ivens T, Schel P, et al. (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother Feb 42: 269–276.
[13]
Nauwelaers D, Houtte MV, Winters B, Steegen K, Baelen KV, et al. (2011) A Synthetic HIV-1 Subtype C Backbone Generates Comparable PR and RT Resistance Profiles to a Subtype B Backbone in a Recombinant Virus Assay. PLoS ONE May 6: e19643. doi:10.1371/journal.pone.0019643.
[14]
Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kaleebu P, et al. (2010) Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. Journal of Virological Methods 163: 505–508. doi:10.1016/j.jviromet.2009.11.011.Affordabl？e.
[15]
Hamers R, Oyomopito R, Kityo C, Phanuphak P, Siwale M, et al. (2011) Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol Apr 21:
[16]
Rhee S-J, Gonzales M, Kantor R, Betts B, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 31: 298–303.
[17]
Virco B (n.d.) Virco Biological Cut-offs. Available:http://www.vircolab.com/hiv-resistance-p？roducts/vircotype-hiv-1/cut-offs-for-vir？cotype-hiv-1/biological-cut-offs. Accessed 5 June 2010.
[18]
Vergara IA, Norambuena T, Ferrada E, Slater AW, Melo F (2008) StAR: a simple tool for the statistical comparison of ROC curves. BMC Bioinformatics 9: 265. Available:http://protein.bio.puc.cl/star.html. Accessed 12 May 2011.
[19]
Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, et al. (2010) Update of the drug resistance mutations in HIV-1: December 2010. Topics in HIV medicine : a publication of the International AIDS Society, USA. 18. : 156–163. Available:http://www.ncbi.nlm.nih.gov/pubmed/21245？516.
[20]
Choe S, Stawiski E, Parkin N (n.d.) Interpretation of Drug Susceptibility and Replication Capacity Results from Subtype C HIV-1 Protease/RT Is Not Influenced by the Subtype of the Resistance Test Vector. XV International HIV Drug Resistance Workshop Bridgetown, Barbados.
[21]
Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, et al. (2002) Comparative Analysis of Two Commercial Phenotypic Assays for Drug Susceptibility Testing of Human Immunodeficiency Virus Type 1. J Clin Microbiol 40: 31–35. doi:10.1128/JCM.40.1.31.
[22]
VanHoutte M, Picchio G, Van Der Borght K, Pattery T, Lecocq P, et al. (2009) A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol Oct 81: 1702–1709.
[23]
Petropoulos C, Parkin N, Limoli K, Lie Y, Wrin T, et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother Apr 44: 920–928.
[24]
Steegen K, Bronze M, Van Craenenbroeck E, Winters B, Van der Borght K, et al. (2010) A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences. AIDS Res Ther Oct 15: 38.
[25]
Ari？n K, Abraha A, Qui？ones-Mateu M, Kestens L, Vanham G, et al. (2005) The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol Jul 79: 8979–8990.
[26]
Wang K, Samudrala R, Mittler JE (2004) Antivirogram or PhenoSense: a comparison of their reproducibility and an analysis of their correlation. Antiviral Therapy Oct 9: 703–712.
[27]
Zhang J, Rhee S, Taylor J, Shafer RW (2005) Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays. J Acquir Immune Defic Syndr 38: 439–444.
